Olean Times Herald

-Ultra-long- acting subcutaneous (SQ) injection formulation of small molecule ASC30 demonstrated a 36-day half-life in patients with obesity, supporti...

HONG KONG , March 20, 2025 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX:1672, "Ascletis") announces it will host an Obesity Portfolio Webinar on April 2...

HONG KONG , March 11, 2025 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX:1672, "Ascletis") announces encouraging pharmacokinetic and weight loss data fro...

- ASC30 oral once-daily tablet demonstrated a 6.3% mean body weight reduction from baseline after 28-day treatment in multiple ascending dose (MAD) c ...

HONG KONG , Jan. 21, 2025 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX:1672, "Ascletis") announces today positive topline results from its U.S. single a...